Business
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. “Despite its prevalence, there continues to be significant unmet need in the treatment of OA due to the lack of innovation in therapeutic advancements since the launch of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the U.S.,” said Frank D. Lee. “We are committed to advancing research and addressing the pressing needs of OA patients worldwide. As part of this commitment, we are proud to build on our established leadership by contributing valuable data to the PROBE initiative including findings from our ASCEND study, which is evaluating our investigational targeted gene therapy, PCRX-201, for the treatment of osteoarthritis. Pacira is among a select group of U.S.-based companies to join the European Innovative Health Initiative (IHI)-funded public-private consortium, which brings together 38 partners from academia, industry, patient organizations, regulatory agencies, and health professionals with the goal of transforming the diagnosis and treatment of OA through the following initiatives: Creating a regulation-compliant database network to analyze unidentified patient data from multiple OA cohorts and registries.Using AI models to predict disease progression and support personalized medicine.Developing novel multi-modal trial endpoints for better treatment evaluation.Providing tools for shared decision-making between patients and healthcare providers. With this approach, which will leverage data from over 70 million patients across diverse OA cohorts and real-world registries, PROBE aims to address major limitations in OA research and clinical care, including disease heterogeneity, fragmented datasets, and outdated trial designs. About PaciraPa...